IFW

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS PAPER AND THE DOCUMENTS REFERRED AS BEING ATTACHED OR ENCLOSED HEREWITH ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL OFFICE ON AS EXPRESS MAIL ADDRESSED TO: MAIL STOP AMENDMENT COMMISSIONER FOR

BOX 1459, ALEXANDRIA, VA 22313-1450

Elaine C. Stracker

OIPE

PATENT

Attorney's Docket No.: 00065.01R

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Hale et al.

Serial No.:

10/712,365

Filed:

11/12/2003

Title

DIURETIC AEROSOLS AND METHODS OF MAKING AND USING

THEM

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with their continuing duty of disclosure under 37 CFR §§ §1.97, 1.98 and 1.56, Applicants hereby submit for consideration in the above-identified application the enclosed references. The Information Disclosure statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

For the convenience of the Examiner, the references are listed on a PTO Form 1449 (attached) and copies thereof are enclosed. Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines than an extension and/or other relief is required, Applicants petition for any required relief including any extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 502731**. Please direct all correspondence to the following customer number.

Respectfully submitted,

SEP	2	4	2004
-----	---	---	------

Elaine C. Stracker J.D., Ph.D., Reg. 43,166

Alexza Molecular Delivery Corporation 1001 East Meadow Circle Palo Alto, CA 94303

TEL: (650) 687-3905

FAX: (650) 687-3999

Approved for use through 07/31/2006. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	Application Number	10/712,365
TRANSMITTAL	Filing Date	11/12/2003
FORM	First Named Inventor	Ron L. Hale
(to be used for all correspondence after initial filing)	Art Unit	Not yet known
	Examiner Name	To be assigned
Total Number of Pages in This Submission	Attorney Docket Number	00065.01R

PTO/SB/21 (08-03)

		ENCLOSU	RES (check all that app	y)	
Fee Transmittal Form		Drawing(s))		After Allowance communication to Group
Fee Attached		Licensing-	related Papers		Appeal Communication to Board of Appeals and Interferences
Amendment / Reply		Petition			Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
. After Final		Petition to Provisiona	Convert a I Application		Proprietary Information
Affidavits/decla	aration(s)		Attorney, Revocation Correspondence		Status Letter
Extension of Time Req	nsion of Time Request Terminal Disclaimer			X	Other Enclosure(s) (please identify below):
Express Abandonment	Request	Request for Refund			
Information Disclosure Statement		CD, Number of CD(s)			
Certified Copy of Prior Document(s)	•	Remarks			
Response to Missing I Incomplete Application Response to Munder 37 CFR	n Fo Co Missing Parts Re	nfo. Discl. Stater orm 1449 (3 cop opy of 91 refere eturn Postcard	ies, 4 pages each)		
	SIGNATURE	OF APPLICAN	IT, ATTORNEY, OR AGE	NT	
Firm ALEXZ or Elaine Individual name	ZA MDC, 1001 E. C. Stracker, Ph.E	ast Meadow Cir D., J.D. Telep	rcle, Palo Alto, CA 94303 shone (650)-687-3905		Customer Number 37485
Signature	Vani (1 2			
Date	SEP. 2 4 20	04			

CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the Typed or printed name Elaine C. Stracker SEP. 24 2004 Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FORM PTO-1449 59

ORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00065.01R Application Number: 10/712,365

Applicant: HALE et al.

Filing Date: 11/12/2003 Group Art Unit: Unknown

			U.S. PATENT	DOCUMENTS			
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
-							
,		-					

RELATED ALEXZA MOLECULAR DELIVERY CORPORATION PATENT DOCUMENTS

1 08/04/2003 10/633 876 Hale et al

1.	08/04/2003	10/633,876	Hale et al.	
2.	08/04/2003	10/633,877	Hale et al.	
3.	12/30/2003	10/749,537	Rabinowitz et al.	
4.	12/30/2003	10/749,539	Rabinowitz et al.	
5.	01/27/2004	10/766,149	Rabinowitz et al.	
6.	01/27/2004	10/766,279	Rabinowitz et al.	
7.	01/27/2004	10/766,566	Rabinowitz et al.	
8.	01/27/2004	10/766,574	Rabinowitz et al.	
9.	01/27/2004	10/766,634	Rabinowitz et al.	
10.	01/27/2004	10/766,647	Rabinowitz et al.	
11.	01/28/2004	10/767,115	Rabinowitz et al.	
12.	01/29/2004	10/768,205	Rabinowitz et al.	
13.	01/29/2004	10/768,220	Rabinowitz et al.	
14.	01/29/2004	10/768,281	Rabinowitz et al.	
15.	01/29/2004	10/768,293	Rabinowitz et al.	
16.	01/30/2004	10/769,046	Rabinowitz et al.	
17.	01/30/2004	10/769,051	Rabinowitz et al.	
18.	01/29/2004	10/769,157	Rabinowitz et al.	
19.	01/29/2004	10/769,197	Rabinowitz et al.	
20.	02/09/2004	10/775,583	Rabinowitz et al.	
21.	02/09/2004	10/775,586	Rabinowitz et al.	
22.	03/03/2004	10/791,915	Hale et al.	
23.	03/03/2004	10/792,001	Rabinowitz et al.	

EXAMINER:

DATE CONSIDERED:

)

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

7	Docket Number: 00065.01R	Application Number: 10/712,365
١		
	Applicant: HALE et al.	
	11/12/2003	Group Art Unit: Unknown
	Filing Date: 11/12/2003	

 24 10	3/03/2004	10/1/2501	Hale et al.
)3/03/2004	10/792,013	Rabinowitz et al.
 	03/03/2004		Hale et al.
 	03/03/2004	10/792,239	Hale et al.
 	03/03/2004	10/813,721	Rabinowitz et al.
 		10/813,722	Rabinowitz et al.
 	03/31/2004	10/814,690	Rabinowitz et al.
 		10/814,998	Rabinowitz et al.
 	03/31/2004	10/815,527	Rabinowitz et al.
 32.	04/01/2004	10/816,407	Rabinowitz et al.
 33.	04/01/2004	10/816,492	Rabinowitz et al.
 34.	04/01/2004	10/816,567	Rabinowitz et al.
 35.	04/01/2004	10/912,462	Hale et al.
 36.	08/04/2004	US 2003/0015196	Hodges et al.
 37.	01/23/2003	US 2003/0062042	Wensley et al.
 38.	04/03/2003	US 2003/0209240	Hale et al.
 39.	11/13/2003	US 2003/0000518	Rabinowitz et al.
40.	01/02/2003	US 2003/0005924	
 41.	12000	US 2003/0005925	Hale et al.
 42.	- 12222	US 2003/0007933	Rabinowitz et al.
 43.	12000	US 2003/0007934	Rabinowitz et al.
 44	112222	US 2003/0012737	Rabinowitz et al.
 45		US 2003/0012738	Rabinowitz et al.
 46		US 2003/0012740	Rabinowitz et al.
 47	10000	US 2003/0015189	9 Rabinowitz et al.
 48		US 2003/001519	
49	·	US 2003/001711	4 Rabinowitz et al.
 50	12.000	US 2003/001711	5 Rabinowitz et al.
 5	17.7 (2.0.0.2)	US 2003/001711	
 	2. 01/23/2003	US 2003/001711	
	3. 01/23/2003 64. 01/23/2003	US 2003/00171	

EXAMINER:

Form	PTO-1	449
------	-------	-----

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

lication Number: 10/712,365
oup Art Unit: Unknown

		US 2003/0017119	Rabinowitz et al.	
55.	01/23/2003		Rabinowitz et al.	_
56.	01/23/2003	US 2003/0017120	Rabinowitz et al.	
57.	1/30/2003	US 2003/0021753	Rabinowitz et al.	
58.	01/30/2003	US 2003/0021754		
59.	01/30/2003	US 2003/0021755	Hale et al.	
60.	02/20/2003	US 2003/0035776	Hodges et al.	_
61.	05/15/2003	US 2003/0091511	Rabinowitz et al.	_
62.	05/27/2004	US 2004/010148	Hale et al.	
63	07/31/2003	US 2003/0138382	Rabinowitz	
64		US 2003/0206869	Rabinowitz et al.	
65		US 2004/0009128	Rabinowitz et al.	_
66		US 2004/0096402	Hodges et al.	
67		US 2004/0099269	Hale et al.	
68		US 2004/0105819	Hale et al.	_
69		US 2004/0126326	Rabinowitz et al.	_
70		US 2004/0126327	Rabinowitz et al.	_
71		US 2004/0126328		_
72		US 2004/0126329		_
7:		US 2004/0127481		_
	4. 07/01/2004	US 2004/0127490		
	5. 08/12/2004	US 2004/0156788		
	6. 08/12/2004	US 2004/0156789		
		US 2004/0156790		
		US 2004/0156791		
7	8. 08/12/2004	US 2004/0130791		

FOREIGN PATENT DOCUMENTS

			FOREIGN PATE	NT DOCUMENTS	T ==	0.1.1	Translation
Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	YES NO
		1					
				DATE CONSIDER!	ED.		

EXAMINER:

DATE CONSIDERED:

T	DTC	١ 1	4 40
Form	PIU)- I 4	447

)

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if neces.	sary)
-------------------------------	-------

	511001 4 01 4
Docket Number: 00065.01R	Application Number: 10/712,365
Applicant: HALE et al.	
	12
Filing Date: 11/12/2003	Group Art Unit: Unknown

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	79.	Berkó et al. (2002) "In vitro and in vivo study in rats of rectal suppositories containing furosemide." European Journal of Pharmaceutics and Biopharmaceutics Vol 53:311-315.
	80.	Cavaliere et al. (2002) "Furosemide Protective Effect Against Airway Obstruction." Website http://www.bentham.org/sample-issues/cdt3-3/cavaliere/cavaliere-ms.htm
	81.	Dormans et al. (1996) "Vascular effects of loop diuretics." Cardiovascular Research 32:988-997.
	82.	Faris et al. (2002) "Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomized controlled trials." <i>International Journal of Cardiology</i> Vol. 82:149-158.
,	83.	Iwamoto et al. (2001) "Loop Diuretics and In Vitro Relaxation of Human Fetal and Newborn Mouse Airways." <i>Pediatric Research</i> Vol. 50 No.2: 273-276.
	84.	Nielsen et al. (2000) "Intranasal Administration of Different Liquid Formulation of Bumetanide to Rabbits" <i>International Journal of Pharmaceutics</i> 204:35-41.
-	85.	Nishino et al. (2000) "Inhaled Furosemide Greatly Alleviates the Sensation of Experimentally Induced Dyspnea." Am J Respir Crit Care Med Vol. 161: 1963-1967.
	86.	O'Connor et al. (1991) "Effect of Inhaled Furosemide and Bumetanide on Adenosine 5'-monophosphate- and sodium metabisulfite-induced bronchoconstriction in asthmatic subjects." Am. Rev. Repir. Dis. 146(6): 1329-33.
	87.	Pardeep et al. (2000) "The acute vascular effects of frusemide in heart failure." Br J Clin Pharmacol Vol. 50:9-13.
	88.	Polosa et al. (1993) "Relative Potencies and Time Course of Changes in Adenosine 5'Monophosphate Airway Responsiveness with Inahled Furosemide and Bumetanide in Asthma." J. Allergy Clin. Immunol. 92(2):288-97.
	89.	Polosa et al. (1995) "Inhaled Loop Diuretics and Basal Airway Responsiveness in Man: Evidence of a Role for Cyclo-oygenase Products." Eur. Respir. J 8(4):593-599.
	90.	Shankar et al. (2003) "Loop diuretics: from the Na-K-2Cl transporter to clinical use." Am J Physiol Renal Pysiol. 283:F11-21.
	91.	Shimoyama et al. (2002) "Nebulized Furosemide as a Novel Treatment for Dyspnea in Terminal Cancer Patients." Journal of Pain and Symptom Management Vol. 23 No.1: 73:76.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citatio conformance and not considered. Include a copy of this form with ne	n conforms with MPEP 609. Draw a line through the citation if not in ext communication to applicant.

TION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Sheet 1 of 4
Application Number: 10/712,365
-
Group Art Unit: Unknown
olos, i

				POGLIMENTS			
Examiner	Ref.	Date	U.S. PATENT	T DOCUMENTS Name	Class	Subclass	Filing Date If Appropriate
Initials	No.						
							CENTE

RELATED ALEXZA MOLECULAR DELIVERY CORPORATION PATENT DOCUMENTS Hale et al. 10/633,876 08/04/2003 Hale et al. 10/633,877 08/04/2003 2. Rabinowitz et al. 10/749,537 12/30/2003 3. Rabinowitz et al. 10/749,539 12/30/2003 4. Rabinowitz et al. 10/766,149 01/27/2004 5. Rabinowitz et al. 10/766,279 01/27/2004 6. Rabinowitz et al. 10/766,566 01/27/2004 7. Rabinowitz et al. 10/766,574 01/27/2004 8. Rabinowitz et al. 10/766,634 01/27/2004 9. Rabinowitz et al. 10/766,647 01/27/2004 10. Rabinowitz et al. 10/767,115 01/28/2004 11. Rabinowitz et al. 10/768,205 01/29/2004 12. Rabinowitz et al. 10/768,220 01/29/2004 13. Rabinowitz et al. 10/768,281 01/29/2004 14. Rabinowitz et al. 10/768,293 01/29/2004 15. Rabinowitz et al. 10/769,046 01/30/2004 16. Rabinowitz et al. 10/769,051 01/30/2004 17. Rabinowitz et al. 10/769,157 01/29/2004 18. Rabinowitz et al. 10/769,197 01/29/2004 19. Rabinowitz et al. 10/775,583 02/09/2004 20. Rabinowitz et al. 10/775,586 02/09/2004 21. Hale et al. 10/791,915 03/03/2004 22. Rabinowitz et al. 10/792,001 03/03/2004 23.

23.	03/03/2004	10//92,001	Rabillo Wile		
			DATE CONSII	DERED:	
EXAMINER:		_	1		is sign if not in
			MDED	609. Draw a line through th	e citation if not in

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Application Number: 10/712,365 Docket Number: 00065.01R

Applicant: HALE et al.

Group Art Unit: Unknown Filing Date: 11/12/2003

			10/700 010	XX.141
	24.	03/03/2004	10/792,012	Hale et al.
	25.	03/03/2004	10/792,013	Rabinowitz et al.
	26.	03/03/2004	10/792,096	Hale et al.
	27.	03/03/2004	10/792,239	Hale et al.
	28.	03/31/2004	10/813,721	Rabinowitz et al.
	29.	03/31/2004	10/813,722	Rabinowitz et al.
	30.	03/31/2004	10/814,690	Rabinowitz et al.
	31.	03/31/2004	10/814,998	Rabinowitz et al.
	32.	04/01/2004	10/815,527	Rabinowitz et al.
	33.	04/01/2004	10/816,407	Rabinowitz et al.
	34.	04/01/2004	10/816,492	Rabinowitz et al.
	35.	04/01/2004	10/816,567	Rabinowitz et al.
	36.	08/04/2004	10/912,462	Hale et al.
	37.	01/23/2003	US 2003/0015196	Hodges et al.
	38.	04/03/2003	US 2003/0062042	Wensley et al.
	39.	11/13/2003	US 2003/0209240	Hale et al.
	40.	01/02/2003	US 2003/0000518	Rabinowitz et al.
	41.	01/09/2003	US 2003/0005924	Rabinowitz et al.
	42.	01/09/2003	US 2003/0005925	Hale et al.
	43.	01/09/2003	US 2003/0007933	Rabinowitz et al.
	44.	01/09/2003	US 2003/0007934	Rabinowitz et al.
	45.	01/16/2003	US 2003/0012737	Rabinowitz et al.
	46.		US 2003/0012738	Rabinowitz et al.
	47.	1/16/2003	US 2003/0012740	Rabinowitz et al.
	48.		US 2003/0015189	Rabinowitz et al.
	49.		US 2003/0015190	Rabinowitz et al.
	50.		US 2003/0017114	Rabinowitz et al.
-	51.		US 2003/0017115	Rabinowitz et al.
	52.		US 2003/0017116	Rabinowitz et al.
 	53.		US 2003/0017117	Rabinowitz et al.
	54		US 2003/0017118	Rabinowitz et al.
L	1 27	. 31,23,200		DATE CONSIDERED:

EXAMINER:

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

	BMCCC 2
Docket Number: 00065.01R	Application Number: 10/712,365
Applicant: HALE et al.	
	Group Art Unit: Unknown
Filing Date: 11/12/2003	Citapina

 55.	01/23/2003	US 2003/0017119	Rabinowitz et al.			
 1 22.1	01/23/2003	US 2003/0017120	Rabinowitz et al.	<u> </u>	ļ	
 57.	1/30/2003	US 2003/0021753	Rabinowitz et al.			
 58.	01/30/2003	US 2003/0021754	Rabinowitz et al.		<u> </u>	
 59.	01/30/2003	US 2003/0021755	Hale et al.			
 60.	02/20/2003	US 2003/0035776	Hodges et al.		<u> </u>	
 61.	05/15/2003	US 2003/0091511	Rabinowitz et al.			
 62.	05/27/2004	US 2004/010148	Hale et al.			_
 63.	07/31/2003	US 2003/0138382	Rabinowitz			
 64.	11/06/2003	US 2003/0206869	Rabinowitz et al.			
 65.	01/15/2004	US 2004/0009128	Rabinowitz et al.			
 66.	05/20/2004	US 2004/0096402	Hodges et al.			
 67.	05/27/2004	US 2004/0099269	Hale et al.			
 68.	06/03/2004	US 2004/0105819	Hale et al.			
 69.	07/01/2004	US 2004/0126326	Rabinowitz et al.			
 70.	10004	US 2004/0126327	Rabinowitz et al.			
 $\frac{70}{71}$		US 2004/0126328	Rabinowitz et al.			
 72		US 2004/0126329	Rabinowitz et al.		_	
 73		US 2004/0127481	Rabinowitz et al.			
 $-\frac{1}{74}$		US 2004/0127490				
 75		US 2004/0156788	Rabinowitz et al.		_	
 76		US 2004/0156789				
 $-\frac{1}{77}$		US 2004/0156790		+_		
 78		US 2004/0156791	Rabinowitz et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
				DATE CONSIDER	ED:		

EXAMINER:

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00065.01R	Application Number: 10/712,365

Applicant: HALE et al.

Filing Date: 11/12/2003 Group Art Unit: Unknown

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	79.	Berkó et al. (2002) "In vitro and in vivo study in rats of rectal suppositories containing furosemide." European Journal of Pharmaceutics and Biopharmaceutics Vol 53:311-315.
,	80.	Cavaliere et al. (2002) "Furosemide Protective Effect Against Airway Obstruction." Website http://www.bentham.org/sample-issues/cdt3-3/cavaliere/cavaliere-ms.htm
	81.	Dormans et al. (1996) "Vascular effects of loop diuretics." Cardiovascular Research 32:988-997.
	82.	Faris et al. (2002) "Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomized controlled trials." <i>International Journal of Cardiology</i> Vol. 82:149-158.
•	83.	Iwamoto et al. (2001) "Loop Diuretics and In Vitro Relaxation of Human Fetal and Newborn Mouse Airways." <i>Pediatric Research</i> Vol. 50 No.2: 273-276.
	84.	Nielsen et al. (2000) "Intranasal Administration of Different Liquid Formulation of Bumetanide to Rabbits" <i>International Journal of Pharmaceutics</i> 204:35-41.
-	85.	Nishino et al. (2000) "Inhaled Furosemide Greatly Alleviates the Sensation of Experimentally Induced Dyspnea." Am J Respir Crit Care Med Vol. 161: 1963-1967.
-	86.	O'Connor et al. (1991) "Effect of Inhaled Furosemide and Bumetanide on Adenosine 5'-monophosphate- and sodium metabisulfite-induced bronchoconstriction in asthmatic subjects." Am. Rev. Repir. Dis. 146(6): 1329-33.
	87.	Pardeep et al. (2000) "The acute vascular effects of frusemide in heart failure." Br J Clin Pharmacol Vol. 50:9-13.
	88.	Polosa et al. (1993) "Relative Potencies and Time Course of Changes in Adenosine 5'Monophosphate Airway Responsiveness with Inahled Furosemide and Bumetanide in Asthma." J. Allergy Clin. Immunol. 92(2):288-97.
	89.	Polosa et al. (1995) "Inhaled Loop Diuretics and Basal Airway Responsiveness in Man: Evidence of a Role for Cyclo-oygenase Products." Eur. Respir. J 8(4):593-599.
	90.	Shankar et al. (2003) "Loop diuretics: from the Na-K-2Cl transporter to clinical use." Am J Physiol Renal Pysiol. 283:F11-21.
	91.	Shimoyama et al. (2002) "Nebulized Furosemide as a Novel Treatment for Dyspnea in Terminal Cancer Patients." Journal of Pain and Symptom Management Vol. 23 No.1: 73:76.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation of	conforms with MPEP 609. Draw a line through the citation if not in

SEP 2 1 2004 F

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00065.01R	Application Number: 10/712,365		
Applicant: HALE et al.			

,			U.S. PATENT	DOCUMENTS			
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
						,	

RELATED ALEXZA MOLECULAR DELIVERY CORPORATION PATENT DOCUMENTS

TVI	ED ALEALA IV.	OLLCOLAR DELL			
1.	08/04/2003	10/633,876	Hale et al.		
2.	08/04/2003	10/633,877	Hale et al.		
3.	12/30/2003	10/749,537	Rabinowitz et al.		
4.	12/30/2003	10/749,539	Rabinowitz et al.		
5.	01/27/2004	10/766,149	Rabinowitz et al.		
6.	01/27/2004	10/766,279	Rabinowitz et al.		
7.	01/27/2004	10/766,566	Rabinowitz et al.		
8.	01/27/2004	10/766,574	Rabinowitz et al.		
9.	01/27/2004	10/766,634	Rabinowitz et al.		
10.	01/27/2004	10/766,647	Rabinowitz et al.		
11.	01/28/2004	10/767,115	Rabinowitz et al.		
12.	01/29/2004	10/768,205	Rabinowitz et al.		
13.	01/29/2004	10/768,220	Rabinowitz et al.		
14.	01/29/2004	10/768,281	Rabinowitz et al.		
15.	01/29/2004	10/768,293	Rabinowitz et al.		
16.	01/30/2004	10/769,046	Rabinowitz et al.		
17.	01/30/2004	10/769,051	Rabinowitz et al.		
18.	01/29/2004	10/769,157	Rabinowitz et al.		
19.	01/29/2004	10/769,197	Rabinowitz et al.		
20.	02/09/2004	10/775,583	Rabinowitz et al.		
21.	02/09/2004	10/775,586	Rabinowitz et al.		
	03/03/2004	10/791,915	Hale et al.		
23.	03/03/2004	10/792,001	Rabinowitz et al.		
	1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22.	1. 08/04/2003 2. 08/04/2003 3. 12/30/2003 4. 12/30/2003 5. 01/27/2004 6. 01/27/2004 7. 01/27/2004 9. 01/27/2004 10. 01/27/2004 11. 01/28/2004 12. 01/29/2004 13. 01/29/2004 14. 01/29/2004 15. 01/29/2004 16. 01/30/2004 17. 01/30/2004 18. 01/29/2004 19. 01/29/2004 20. 02/09/2004 21. 02/09/2004 22. 03/03/2004	1. 08/04/2003 10/633,876 2. 08/04/2003 10/633,877 3. 12/30/2003 10/749,537 4. 12/30/2004 10/749,539 5. 01/27/2004 10/766,149 6. 01/27/2004 10/766,279 7. 01/27/2004 10/766,566 8. 01/27/2004 10/766,574 9. 01/27/2004 10/766,634 10. 01/27/2004 10/766,647 11. 01/28/2004 10/768,205 13. 01/29/2004 10/768,281 15. 01/29/2004 10/768,281 15. 01/29/2004 10/769,046 17. 01/30/2004 10/769,051 18. 01/29/2004 10/769,157 19. 01/29/2004 10/769,197 20. 02/09/2004 10/775,583 21. 02/09/2004 10/775,586 22. 03/03/2004 10/791,915	2. 08/04/2003 10/633,877 Hale et al. 3. 12/30/2003 10/749,537 Rabinowitz et al. 4. 12/30/2004 10/766,149 Rabinowitz et al. 5. 01/27/2004 10/766,279 Rabinowitz et al. 6. 01/27/2004 10/766,566 Rabinowitz et al. 7. 01/27/2004 10/766,574 Rabinowitz et al. 8. 01/27/2004 10/766,574 Rabinowitz et al. 9. 01/27/2004 10/766,634 Rabinowitz et al. 10. 01/27/2004 10/766,647 Rabinowitz et al. 11. 01/28/2004 10/767,115 Rabinowitz et al. 12. 01/29/2004 10/768,205 Rabinowitz et al. 13. 01/29/2004 10/768,220 Rabinowitz et al. 14. 01/29/2004 10/768,281 Rabinowitz et al. 15. 01/29/2004 10/768,293 Rabinowitz et al. 16. 01/30/2004 10/769,046 Rabinowitz et al. 17. 01/30/2004 10/769,046 Rabinowitz et al. 18. 01/29/2004 10/769,051 Rabinowitz et al. 19. 01/29/2004 10/769,157 Rabinowitz et al. 20. 02/09/2004 10/769,197 Rabinowitz et al. 21. 02/09/2004 10/775,588 Rabinowitz et al. 22. 03/03/2004 10/775,586 Rabinowitz et al.	1. 08/04/2003 10/633,876 Hale et al. 2. 08/04/2003 10/633,877 Hale et al. 3. 12/30/2003 10/749,537 Rabinowitz et al. 4. 12/30/2003 10/749,539 Rabinowitz et al. 5. 01/27/2004 10/766,149 Rabinowitz et al. 6. 01/27/2004 10/766,579 Rabinowitz et al. 7. 01/27/2004 10/766,566 Rabinowitz et al. 8. 01/27/2004 10/766,574 Rabinowitz et al. 9. 01/27/2004 10/766,634 Rabinowitz et al. 10. 01/27/2004 10/766,647 Rabinowitz et al. 11. 01/28/2004 10/767,115 Rabinowitz et al. 12. 01/29/2004 10/768,205 Rabinowitz et al. 13. 01/29/2004 10/768,220 Rabinowitz et al. 14. 01/29/2004 10/768,281 Rabinowitz et al. 15. 01/29/2004 10/768,293 Rabinowitz et al. 16. 01/30/2004 10/769,046 Rabinowitz et al. 17. 01/30/2004 10/769,051 Rabinowitz et al. 18. 01/29/2004 10/769,157 Rabinowitz et al. 19. 01/29/2004 10/769,157 Rabinowitz et al. 20. 02/09/2004 10/775,588 Rabinowitz et al. 21. 02/09/2004 10/775,586 Rabinowitz et al. 22. 03/03/2004 10/791,915 Hale et al.

EX.	٨	λ.	<i>4</i> 1	N.I	E.	D	٠
EA	n	IJν	ш	Ľ	Æ.	Л	•

DATE CONSIDERED:

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Application Number: 10/712,365 Docket Number: 00065.01R

Applicant: HALE et al.

Group Art Unit: Unknown Filing Date: 11/12/2003

	02/02/2004	10/792,012 I	Iale et al.		
24.	03/03/2004	10///2,012	Rabinowitz et al.		
25.	03/03/2004	10/1/2,012	Iale et al.		
26.	03/03/2004	10/172,000	Hale et al.		
27.	03/03/2004	10/1/2,23/	Rabinowitz et al.		
28.	03/31/2004	10/015,/	Rabinowitz et al.		
29.	03/31/2004	10/015,722	Rabinowitz et al.		
30.	03/31/2004	10/01-1,000	Rabinowitz et al.		
31	03/31/2004	10/01 1355	Rabinowitz et al.		
32		10/015,52	Rabinowitz et al.		
33		10/816,407	Rabinowitz et al.		
34		10/816,492	Rabinowitz et al.		
35	. 04/01/2004	10/816,567	Hale et al.		
36	. 08/04/2004	10/912,462			
37	. 01/23/2003	US 2003/0015196	Hodges et al.		
38	3. 04/03/2003	US 2003/0062042	Wensley et al.		
39). 11/13/2003	US 2003/0209240	Hale et al.		
4	0. 01/02/2003	US 2003/0000518	Rabinowitz et al.		
4	1. 01/09/2003	US 2003/0005924	Rabinowitz et al.		
	2. 01/09/2003	US 2003/0005925	Hale et al.		
4	3. 01/09/2003	US 2003/0007933	Rabinowitz et al.		
4	4. 01/09/2003	US 2003/0007934	Rabinowitz et al.		
	5. 01/16/2003	US 2003/0012737	Rabinowitz et al.		
	6. 01/16/2003	US 2003/0012738	Rabinowitz et al.		
	7. 1/16/2003	US 2003/0012740	Rabinowitz et al.		
	18. 01/23/2003	US 2003/0015189	Rabinowitz et al.		
	19. 01/23/2003	US 2003/0015190	Rabinowitz et al.		
	50. 01/23/2003	US 2003/0017114	Rabinowitz et al.		
	51. 01/23/2003	US 2003/0017115	Rabinowitz et al.	 	
	52. 01/23/2003	US 2003/0017116		 	
	53. 01/23/2003	US 2003/0017117	Rabinowitz et al.		
	54. 01/23/2003	US 2003/0017118	Rabinowitz et al. DATE CONSIDERE		

EXAMINER:

Form	PT	O-1	449
LOIL		~ -	

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00065.01R	Application Number: 10/712,365			
Applicant: HALE et al.				
Filing Date: 11/12/2003	Group Art Unit: Unknown			

				Rabinowitz et al.			
3	2003		03/0017119		 	_	
3	2003		03/0017120	Rabinowitz et al.			
,	003		03/0021753	Rabinowitz et al.			
)3	2003		003/0021754	Rabinowitz et al.	 +		
)3	2003		003/0021755	Hale et al.	 		
)3	2003		003/0035776	Hodges et al.	 		
03	2003	US 20	003/0091511	Rabinowitz et al.			
04	2004	US 20	004/010148	Hale et al.	 		
03	2003	US 20	003/0138382	Rabinowitz	 		
	2003	US 2	003/0206869	Rabinowitz et al.	 		
04	/2004	US 2	004/0009128	Rabinowitz et al.	 		
	/2004	US 2	004/0096402	Hodges et al.	 		
	/2004	US 2	2004/0099269	Hale et al.	 		
	/2004	US 2	2004/0105819		 		
	/2004	US 2	2004/0126326		 		
	/2004	US 2	2004/0126327	Rabinowitz et al.	 		
	/2004	US	2004/0126328	Rabinowitz et al.	 		
	/2004	US	2004/0126329	Rabinowitz et al.	 		
	1/2004	US	2004/0127481	Rabinowitz et al.	 		
	1/2004		2004/0127490				
	2/2004		2004/0156788		 		
		l			 		
_							
00	2/2004 2/2004 /2004 2/2004	US US	2004/0156789 2004/0156790 2004/0156790	Rabinowitz et al. Rabinowitz et al.			

FOREIGN PATENT DOCUMENTS

			FOREIGN PATE	NI DOCUMENTS		Cultalaga	Translation
Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	YES NO
				DATE CONSIDER	<u>l</u> ED:		

EXAMINER:

DATE CONSIDERED:

•		Blick 101 1			
Form PTO-1449	Docket Number: 00065.01R Application Number: 10/712,365				
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant: HALE et al.				
(Use several sheets if necessary)	Filing Date: 11/12/2003	Group Art Unit: Unknown			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	79.	Berkó et al. (2002) "In vitro and in vivo study in rats of rectal suppositories containing furosemide." European Journal of Pharmaceutics and Biopharmaceutics Vol 53:311-315.
	80.	Cavaliere et al. (2002) "Furosemide Protective Effect Against Airway Obstruction." Website http://www.bentham.org/sample-issues/cdt3-3/cavaliere/cavaliere-ms.htm
	81.	Dormans et al. (1996) "Vascular effects of loop diuretics." Cardiovascular Research 32:988-997.
	82.	Faris et al. (2002) "Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomized controlled trials." <i>International Journal of Cardiology</i> Vol. 82:149-158.
	83.	Iwamoto et al. (2001) "Loop Diuretics and In Vitro Relaxation of Human Fetal and Newborn Mouse Airways." <i>Pediatric Research</i> Vol. 50 No.2: 273-276.
	84.	Nielsen et al. (2000) "Intranasal Administration of Different Liquid Formulation of Bumetanide to Rabbits" International Journal of Pharmaceutics 204:35-41.
•	85.	Nishino et al. (2000) "Inhaled Furosemide Greatly Alleviates the Sensation of Experimentally Induced Dyspnea." Am J Respir Crit Care Med Vol. 161: 1963-1967.
-	86.	O'Connor et al. (1991) "Effect of Inhaled Furosemide and Bumetanide on Adenosine 5'-monophosphate- and sodium metabisulfite-induced bronchoconstriction in asthmatic subjects." Am. Rev. Repir. Dis. 146(6): 1329-33.
	87.	Pardeep et al. (2000) "The acute vascular effects of frusemide in heart failure." Br J Clin Pharmacol Vol. 50:9-13.
	88.	Polosa et al. (1993) "Relative Potencies and Time Course of Changes in Adenosine 5'Monophosphate Airway Responsiveness with Inahled Furosemide and Bumetanide in Asthma." J. Allergy Clin. Immunol. 92(2):288-97.
	89.	Polosa et al. (1995) "Inhaled Loop Diuretics and Basal Airway Responsiveness in Man: Evidence of a Role for Cyclo-oygenase Products." <i>Eur. Respir. J</i> 8(4):593-599.
	90.	Shankar et al. (2003) "Loop diuretics: from the Na-K-2Cl transporter to clinical use." Am J Physiol Renal Pysiol. 283:F11-21.
	91.	Shimoyama et al. (2002) "Nebulized Furosemide as a Novel Treatment for Dyspnea in Terminal Cancer Patients." Journal of Pain and Symptom Management Vol. 23 No.1: 73:76.

EXAMINER:	DATE CONSIDERED:		
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in			

conformance and not considered. Include a copy of this form with next communication to applicant.